БЛОГ

Jul 8, 2020

This Company Wants to Rewrite the Future of Genetic Disease

Posted by in categories: biotech/medical, genetics

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can’t do.

Comments are closed.